Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Public Knowledge-Based Applications Appropriate for Propranolol, Levonorgestrel: Panel
April 23, 2014
- Health Minister Wary about Annual Drug Price Cuts, but Aso, Amari Give Backing
April 23, 2014
- Min. Tamura Positive about Mixed Care Discussions with Govt Panel
April 22, 2014
- MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
- DPJ Member Nagatsuma Asks MHLW to Consider Criminal Complaint over SIGN Trial
April 18, 2014
- New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
- Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
- Govt Deregulation Panel Tenders Prerequisites for Envisaged Mixed Care System
April 17, 2014
- MHLW to Mull Applying Mixed Care Scheme to Low Cost-Effective Drugs: Minister
April 17, 2014
- Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
- PAFSC’s First Committee to Review Canagliflozin, Japan’s 5th SGLT-2 Inhibitor
April 15, 2014
- Pharma Leaders Push Abe Govt to Permanently Introduce Key Premium, R&D Tax Credit
April 15, 2014
- MHLW Panel on Counterfeit Drugs Holds First Meeting
April 14, 2014
- MHLW Diovan Panel Finalizes Report following Fine-Tuning
April 14, 2014
- “Transparency Must Be Ensured” for Funding by Pharmas: Minister
April 14, 2014
- Number of High-Cost New Drugs to Be Reimbursed Under Fee-for-Service System: Chuikyo
April 14, 2014
- Japan NIH Will Have Research Topic-Based Units to Stem Sectionalism: Official
April 11, 2014
- Japanese NIH-Related Bills Clear Lower House
April 11, 2014
- 14-Day Prescription Limit to Be Ruled Out for Anti-HIV Drug Tivicay
April 11, 2014
- Official Says Health Ministry Will Notify Industry about Electronic Data Submissions around June
April 11, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…